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glomerulonephritis: association with 
inhibition of Macrophage caspase-1 
activity via Very late antigen-4 
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Crescentic glomerulonephritis (CGN) is the most aggressive form of GN and, if 
untreated, patients can progress to end-stage renal failure within weeks of presentation. 
The α4β1 integrin very late antigen-4 (VLA-4) is an adhesion molecule of fundamental 
importance to the recruitment of leukocytes in inflammation. We addressed the role 
of VLA-4 in mediating progressive renal injury in a rat model of CGN using a small 
tellurium compound. AS101 [ammonium trichloro(dioxoethylene-o,o′)tellurate]. This 
compound has been previously shown to uniquely inhibit VLA-4 activity by redox 
inactivation of adjacent thiols in the exofacial domain of VLA-4. The study shows that 
administration of AS101 either before or after glomerular basement membrane anti-
serum injection ameliorates crescent formation or preserves renal function. This was 
associated with profound inhibition of critical inflammatory mediators, accompanied by 
decreased glomerular infiltration of macrophages. Mechanistic studies demonstrated 
vla-4 inactivation on glomerular macrophages both in  vitro and in  vivo as well as 
inhibition of caspase-1 activity. Importantly, this cysteine protease activity modification 
was dependent on VLA-4 inactivation and was associated with the anti-inflammatory 
activity of AS101. We propose that inactivation of macrophage VLA-4 by AS101 in vivo 
results in a decrease of inflammatory cytokines and chemokines produced in the 
glomeruli of diseased rats, resulting in decreased further macrophage recruitment and 
decreased extracellular matrix expansion. Thus, AS101, which is currently in clinical 
trials for other indications, might be beneficial for treatment of CGN.
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inTrODUcTiOn
The hallmark of human anti-glomerular basement membrane (GBM) disease is the production 
of autoantibodies targeting the non-collagenous (NC1) domain of the α3 chain of type IV 
collagen found in the GBM (1) leading to crescent formation and crescentic glomerulonephritis 
(CGN). CGN is the most aggressive form of glomerular inflammation, which presents clinically 
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as rapidly progressive glomerulonephritis. It is characterized 
by disruption of the GBM, which leads to infiltration and 
proliferation of inflammatory cells such as macrophages in 
Bowman’s space (2).
The glomerulonephritis is associated with interstitial nephritis 
in many patients with anti-GBM disease and in animal models 
of CGN as well (3, 4). The inflammatory process gives way to 
glomerulosclerosis, interstitial fibrosis, tubular atrophy, and renal 
failure.
Although the pathogenesis of CGN is incompletely under-
stood and likely involves several convergent pathways, there 
is general agreement that circulating mononuclear phagocytes 
play a central role. Administration of nephrotoxic serum to 
rodents results in a severe proliferative and necrotizing GN 
that is characterized by glomerular crescent formation and 
accumulation of leukocytes (2–4). It is thought that infiltrating 
cells release inflammatory mediators that influence the behavior 
of glomerular, tubular, and interstitial cells. This interaction 
between infiltrating and resident cells leads to cellular prolifera-
tion, matrix expansion, and may ultimately lead to glomerular 
sclerosis and interstitial fibrosis. Monocytes and macrophages 
appear to have a critical role, as ablation of macrophages in 
murine CGN reduced glomerular injury and improved renal 
function (5). Infiltrating glomerular macrophages are the major 
source of IL-1 (6) and tumor necrosis factor (TNF) (7). TNFα 
was shown to promote VCAM-1 and ICAM-1 glomerular 
expression and the recruitment of PMNs and lymphocytes were 
markedly reduced in TNF-deficient mice in experimental GN 
induced by anti-GBM antibody (8). Thus, strategies that reduce 
monocyte macrophage infiltration could be a promising avenue 
for complementary therapy of CGN.
Another strategy to prevent leukocyte infiltration in the 
kidney could be to interrupt the interaction between endothelial 
molecules involved in cell adhesion and their ligands on circulat-
ing inflammatory cells. The α4β1 integrin or very late antigen-4 
(VLA-4) is expressed mainly on monocytes, lymphocytes, and 
eosinophils (9). AS101 is a potent in vitro and in vivo tellurium 
immunomodulator, with a wealth of potential therapeutic appli-
cations (10, 11). The compound is non-toxic and is currently in 
phase II/III studies in patients with cervical tumors and in phase 
I/II studies in patients with aging macular degeneration. From 
a mechanistic point of view, much of the biological activity of 
AS101 is directly related to its chemical redox interactions with 
vicinal thiols in the exofacial domain of VLA-4 (12), enabling the 
compound to mediate such diverse effects as abrogation of the 
acquired drug resistance of acute myelogenous leukemia (12) and 
amelioration of experimental autoimmune encephalomyelitis 
(13). The specific redox-modulating activities of AS101 result 
in a variety of beneficial biological effects in diverse preclinical 
and clinical studies (14). The anti-inflammatory properties were 
found crucial for the clinical activities of AS101, including the 
protective effects of AS101 in autoimmune diseases (15, 16) 
and in septic mice (17). The same thiol–redox interactions of 
AS101 enabled it to exert beneficial effects in a variety of tumor 
models in mice and humans where AS101 had clear antitumor 
effects (18, 19). Importantly, as part of its activity, AS101 exerts 
nephroprotective effects. It was able to reduce the level of immune 
complex deposition in the glomeruli, reduce proteinuria, prevent 
glomerular hypercellularity and mesangial expansion, and reduce 
the mean glomerular volume in a murine model of systemic lupus 
erythematosus (16) and prevent kidney damage in a murine 
model of septic peritonitis (17).
The anti-inflammatory properties of AS101 coupled with its 
unique mode of VLA-4 inactivation prompted us to evaluate 
its potential beneficial activities in CGN and determine the 
role of VLA-4 inactivation in these effects. In the present study, 
we demonstrate that administration of AS101 both before and 
after induction of CGN by αGBM injection ameliorates dam-
age to the glomeruli and preserves renal function. This was 
associated with profound inhibition of inflammatory media-
tors and a decreased infiltration of macrophages. Mechanistic 
studies demonstrated that these effects were associated with 
vla-4 inactivation on macrophages and inhibition of caspase-1 
activity in a VLA-4-dependent fashion. These data suggest that 
AS101 could have clinical potential as a therapeutic approach to 
glomerulonephritis.
MaTerials anD MeThODs
reagents
The reagents were as follows: fibronectin (FN) (Sigma; Rehovot, 
Israel) VCAM-1(R&D Biosystems, Minneapolis, MN, USA); 
BSA (Sigma); XTT  cell proliferation kit (Biological Industries, 
Bet Haemek, Israel); FAM FLICA Caspase-3,7 and caspase-1 
detection kit (Immunochemistry Technologies LLC, MN, USA); 
anti Cd49d, anti cd49e (Serotec, NC, USA); Staphylococcus aureus 
Cowan I (SAC) (Calbiochem-Behring Corp., La Jolla, CA, USA). 
LPS (Sigma); mouse anti-rat CD68 (ED1) (Serotec); rabbit 
anti-rat FN (Cedarlane, Burlington, ON, Canada); anti-mouse 
IL-18 (R&D Biosystems); anti-mouse IL-1β (Santa Cruz, Santa 
Cruz, CA, USA); anti αTubulin (Santa Cruz); anti-rat Thy-
1.1(Cederlane); sheep anti-rat GBM (Probetex, San Antonio, TX, 
USA); rat IL-1β, IL-18, and TNFα ELISA kits (BiosourceThermo 
Fisher, Waltham, MA, USA); rat connective tissue growth fac-
tor (CTGF) and monocyte chemoattractant protein-1 (MCP-1) 
ELISA kits (MyBiosource, San Diego CA, USA). Creatinine and 
albumin assay kits (Abcam, San Francisco, CA, USA); AS101 
(supplied by M. Albeck, Bar-Ilan University, Ramat Gan, Israel).
animals
Male Sprague-Dawley rats (180–200  g) were housed in indi-
vidual metabolic cages with unlimited access to food and water. 
Experiments conformed to approved institutional protocols 
and were approved by the Institutional Animal Care and Use 
Committee.
experimental cgn
Rats were presensitized on day −5 by a subcutaneous injection 
of 6.25 mg sheep IgG in 0.5 ml emulsion (1:1 v/v) with Freund’s 
complete adjuvant. Glomerulonephritis was induced on day 0 by 
a single intravenous injection of 105 mg/kg sheep anti-rat GBM 
(αGBM). Experimental groups were as follows: daily i.p. injection 
with PBS without αGBM administration (negative PBS control); 
daily injection with PBS of αGBM-induced rats (positive control) 
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and three treatment groups of daily i.p. injections with AS101 
(100 μg/rat): starting 1 day before, 3 days after, or 6 days after 
αGBM administration.
isolation of glomeruli
Glomeruli were isolated from the renal cortex of rats using 
the differential sieving method (20). The purity of glomeruli 
was >95%.
isolation and culture of glomerular 
Mesangial cells
Isolated glomeruli were cultured in Dulbecco’s modified Eagle’s 
medium containing 5.5  mM d-(+)-glucose; 20% fetal bovine 
serum, 100  μg/ml streptomycin, 100  μg/ml penicillin, and 
2 mM l-glutamine, at 37°C in 5% CO2. After 10 days, the cells 
had the typical appearance of spindle-shaped bundles, and no 
polygonal endothelial or epithelial cells could be detected. Cells 
stained positive with a rabbit polyclonal anti-rat Thy-1.1 antibody 
(mesangial cell marker).
isolation and culture of glomerular 
Macrophages
Glomeruli were cultured in Eagle’s MEM, containing 10% FCS 
at 37°C in a 5% CO2/air atmosphere for 3 days. Glomeruli were 
removed by decanting the medium after vigorous agitation. 
Adherent macrophages were removed by incubation for 3 min 
with trypsin–versene solution. Cells harvested were used imme-
diately. These cells were 90% positive for ED1.
Western Blot analysis
Isolated glomeruli were lysed with lysis buffer [1 M Tris (pH = 7.4), 
1.5 M NaCl, 1% Triton-X, 10% glycerol, 50 mM EDTA (pH = 8), 
0.1  M sodium vanadate, 0.1  M PMSF, 0.1% protease inhibitor 
cocktail]. Samples were boiled for 5 min, electrophoresed on 15% 
or SDS-PAGE, transferred to nitrocellulose, and immunoblotted 
with specific antibodies (IL1β, IL-18). Blots were developed using 
horseradish peroxidase-conjugated secondary Abs and the ECL 
detection system.
Quantitation of caspase activity
Isolated glomerular extracts were prepared in Tris/acetate buffer 
(pH 7.5) at 30°C. The extracts were centrifuged at 12,000 ×  g 
for 10  min, and the supernatant was collected. A volume of 
supernatant equivalent to 100  μg of protein was assayed for 
caspase-1 or caspase-3 activity using the colorimetric caspase-1 
and -3 assay kits.
Quantitation of cytokine levels
IL-1β, TNF-α, CTGF, MCP-1, and IL-18 ELISA kits were used for 
the quantitative measurement of these cytokines either in rat sera 
or urine, in supernatants of cultured cells or in glomerular lysates.
attachment assay for evaluation  
of Vla-4 activity
96-well plates were coated with 80 μL of FN, VCAM-1, or BSA. 
Cells were incubated in the wells for 1 h with or without AS101 
and were washed three times. The attached cells were tested by the 
colorimetric XTT (2,3-bis[2-methoxy-4-nitro-S-sulfophenynl]
H-tetrazolium-5-carboxanilide inner salt) assay at 450 nm.
renal histology
Resected kidneys were cut by a coronal section through the mid 
portion of the kidney. One-half was fixed in 10% buffered forma-
lin. Paraffin blocks were prepared, 3 μM sections were cut from 
each block and stained with hematoxylin-eosin and periodic acid 
Schiff stains for detection of crescent formation.
immunohistochemistry
For ED-1 staining, fixed paraffin embedded kidney sections were 
incubated for 1 h with mouse anti-ED-1 (1:100) followed by horse 
anti-mouse Biotin-conjugated (1:500) antibodies. After incuba-
tion with secondary antibodies, the sections were incubated with 
HRP-streptavidin followed by DAB for an additional, washed and 
exposed to hematoxylin. Glomerular macrophages were counted 
under light microscope. One hundred glomeruli were counted/
sample. For FN staining, the sections were incubated with 
rabbit anti-rat FN (1:100) followed by horse anti-rabbit Biotin-
conjugated (1:500) antibodies. The sections were then incubated 
with HRP-streptavidin followed by DAB, washed, and exposed to 
hematoxylin. FN expansion was scored in 100 glomeruli/sample 
as follows: grade 0—no staining; grade 1—staining occupying up 
to 25% of glomerular surface area; grade 2—staining occupying 
25–50% of glomerular surface area; grade 3—staining occupying 
more than 50% of glomerular surface area.
Fluorescence-activated cell sorter (Facs) 
analysis
Rats were treated with anti-GBM and PBS or with anti-GBM and 
AS101 (+3). At 2  weeks after anti-GBM administration, mac-
rophages were isolated from glomeruli of rats and evaluated for 
VLA-4 expression by FACS analysis. VLA-4 expression on isolated 
glomerular macrophages was determined after incubation with 
FITC Mouse Anti-Rat CD49d (serotec) by FACS [FACStar plus 
(Becton Dickinson) flow cytometer] using The Flow Jo software.
statistical analysis
Data are presented as mean ±  SE. For comparisons between 
groups in the in vivo and in vitro studies, we used the one- or 
two-way ANOVA. Linear correlation analysis (Pearson correla-
tion) was applied to determine the correlation and association 
between parameters. Two-tailed p < 0.05 was considered statisti-
cally significant. The software used for all statistical analysis was 
IBM SPSS Statistics 21.
resUlTs
administration of as101 ameliorates 
crescent Formation and Preserves renal 
Function in experimental cgM
Rats were induced for CGM as described in Section “Materials 
and Methods.” Daily i.p. injections of AS101 (100  μg/rat) 
preserved renal function (Figure 1) as evidenced by decreased 
FigUre 1 | Treatment with as101 preserves kidney function in crescentic glomerulonephritis. GN was induced by a single intravenous injection of αGBM 
[sheep anti-rat glomerular basement membrane (GBM)] in rats presensitized 5 days earlier with sheep IgG, as described in Section “Materials and Methods.” 
Experimental groups were as follows: daily i.p. injection with PBS without αGBM administration (negative control); daily injection with PBS of αGBM-induced rats 
(positive control) and three treatment groups of daily i.p. injections with AS101 (100 μg/rat) starting 1 day before (−1), 3 days after (+3), or 6 days after (+6) the 
αGBM administration. Serum creatinine (a) and proteinuria (B) were recorded on days 0, 1, 3, 5, 7, 9, 11, 14, 16, 19, and 21. Albuminuria (c) was recorded on 
days 0, 7, 14, and 21. Data are presented as mean ± SE of eight rats/group for each time point. *p < 0.05 decrease vs. αGBM. **p < 0.01 decrease vs. αGBM; the 
two-way ANOVA was used.
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serum creatinine levels (Figure  1A) and decreased proteinuria 
(Figure  1B) and albuminuria (Figure  1C). These effects were 
marked and significant when treatment started 1 day before 
αGBM administration [AS101(−1)] or 3  days after αGBM 
administration [AS101(+3)]. Starting treatment 6  days after 
αGBM administration [AS101(+6)] still significantly improved 
renal function, although the effect was more modest.
Crescent formation in some rats was already evident 1 week 
after αGBM administration. This pathology was increased in the 
subsequent weeks (Figure  2). Treatment with AS101 before or 
after αGBM administration significantly ameliorated crescent 
formation at all time points (Figure 2B).
as101 regulates il-18, il-1β, and 
caspase-1 activity and ameliorates 
Kidney Pathology
It is well established that in experimental CGN IL-18 and IL-1β 
contribute to crescent formation and inflammatory cell recruit-
ment (21, 22). For cytokine evaluation, we chose the 2  weeks’ 
time point in order to allow a reasonable time for the AS101(+6) 
protocol to be effective. IL-18 levels in both serum and urine 
were significantly increased 2 weeks after αGBM administration 
(Figures  3A,B). Treatment with AS101 either before or after 
αGBM administration significantly decreased IL-18 levels in 
serum as well as in urine. Moreover, glomerular IL-18 protein 
expression was also considerably decreased in treated rats 
(Figure 3C). This decrease was significant in all three regimens 
of AS101 administration. Importantly, the regulation of IL-18 by 
AS101 was positively and significantly correlated with disease 
severity (proteinuria) as analyzed by Pearson correlation test 
(Figure S1A in Supplementary Material).
IL-18 is synthesized as an inactive precursor that lacks a secre-
tion signal sequence and is proteolytically activated by Caspase-1 
(23). We therefore evaluated the effect of AS101 on caspase-1 
activity in glomeruli of treated rats. Figure  3D shows a sig-
nificant increase in glomerular caspase-1 activity at 2 weeks post 
αGBM administration, which was dramatically and significantly 
decreased by all three AS101 treatment regimens.
These results prompted us to evaluate levels of IL-1β, an 
inflammatory cytokine also proteolytically activated by cas-
pase-1 (24–26). Figure  4 shows that similar to IL-18, serum 
and urine levels of IL-1β were substantially and significantly 
increased 2  weeks after αGBM administration. Again, all 
three AS101 treatment regimens significantly decreased IL-1β 
detectable in serum and in urine at 2  weeks post αGBM 
administration (Figures  4A,B). Similarly, glomerular IL-1β 
protein was significantly decreased following AS101 treatment 
FigUre 2 | Treatment with as101 decreases crescent formation in crescentic glomerulonephritis. Treatment protocol was as described in Figure 1 with 
one modification. Experimental groups were as follows: daily i.p. injection with PBS without αGBM administration (control); daily injection with PBS of αGBM-induced 
rats (αGBM only) and two treatment groups of αGBM-induced rats with daily i.p. injections of AS101 (100 μg/rat) starting 1 day before (–1), or 6 days after (+6) the 
αGBM administration. Groups were tested weekly until week 4. Treatment starting at day 3 (+3) was tested only at week 4. Renal Histology was performed on 
kidney sections for detection of crescents formation on week 2 (a). The percentage of glomeruli with crescents was evaluated in 100 glomeruli/rat on weeks 1, 2, 3, 
and 4 after αGBM administration (B). Data are presented as mean ± SE of 8 rats/group for each time point. #p < 0.01 increase vs. control; *p < 0.05 decrease vs. 
αGBM. **p < 0.01 decrease vs. αGBM. The two-way ANOVA was used.
FigUre 3 | Treatment with as101 decreases il-18 protein levels and glomerular caspase-1 activity in crescentic glomerulonephritis. Treatment 
protocol was as described in Figure 2. Serum (a), urine (B), and glomerular (c). IL-18 expression was evaluated 2 weeks after αGBM administration. Glomerular 
caspase-1 activity (D) was evaluated 2 weeks after αGBM administration. Data are presented as mean ± SE of 7–8 rats/group. Healthy controls (N = 3). #p < 0.01 
increase vs. control; **p < 0.01 decrease vs. αGBM. The one-way ANOVA was used.
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FigUre 4 | Treatment with as101 decreases il-1β protein levels in crescentic glomerulonephritis. Treatment protocol was as described in Figure 2. 
Serum (a), urine (B) and glomerular (c) IL-1β expression were evaluated 2 weeks after αGBM administration. Data are presented as mean ± SE of 7–9 rats/group. 
Healthy controls (N = 3). #p < 0.01 increase vs. control; **p < 0.01 decrease vs. αGBM. The one-way ANOVA was used.
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(Figure  4C). Importantly, both serum and urine IL-β levels 
were positively and significantly correlated with % glomeruli 
with crescent formation and with proteinuria (Figures S1B,C 
in Supplementary Material).
regulation of TnFα expression and 
caspase-3 activity
IL-18 is known to induce production of proinflammatory 
cytokines like TNFα and IL-1β (27). Furthermore, neutralization 
of endogenous IL-18 and TNF-α has been reported to reduce 
crescent formation, and tubulointerstitial scarring, with preser-
vation of renal function (8, 21). Figure  5A shows that TNFα 
levels were strongly elevated in diseased rats, and there was a 
significant reduction in serum TNFα levels by all three AS101 
treatment regimens. Moreover, there was a significant positive 
correlation between serum and urine IL-18 and IL-1β and TNFα 
(Figure S1D in Supplementary Material). TNFα can promote 
apoptosis following ligation of its receptor (28). Glomerular 
caspase-3 activity, the hallmark of apoptosis, was significantly 
increased in diseased rats and was decreased by AS101 in all 
treatment regimens (Figure  5B). A strong positive correlation 
between serum TNFα levels and glomerular caspase-3 activity 
supports a connection between these two parameters (Figure 
S1E in Supplementary Material).
as101 reduces Fn accumulation in the 
glomeruli
Fibronectin is a multifunctional matrix protein that 
increases during glomerular injury. During inflammation, both 
glomerular  accumulation and increased synthesis of FN have 
been reported (29).
Figures 5C,D show a dramatic increase in FN accumulation 
in glomeruli of diseased rats. Treatment with AS101 significantly 
inhibited this process irrespective of whether AS101 was admin-
istered starting before or after αGBM administration. A strong 
positive correlation was found between FN accumulation and 
proteinuria.
as101 regulates Macrophage infiltration 
into the glomeruli
Monocyte/Macrophages play an important role in the induc-
tion of CGN and glomerular injury (5). Their accumulation 
has been associated with increased IL-1β and IL-18 levels in 
various inflammatory states (30). Immunohistochemical analy-
sis of kidneys from αGBM-induced rats showed a significant 
decrease in infiltrating ED1+ cells at all time points examined, 
by all three regimens of AS101 administration (Figures 6A,B). 
Furthermore, a positive and significant correlation was found 
between glomerular macrophage accumulation and levels of 
serum and urine IL-1β (Figure S2A in Supplementary Material) 
and IL-18 (Figure S2B in Supplementary Material). These results 
are in line with the known role of these inflammatory cytokines in 
macrophage accumulation and suggest that AS101 might reduce 
glomerular macrophage accumulation by inhibiting IL-1β and 
IL-18 production.
We also examined CTGF and MCP-1, two factors involved 
in monocytes recruitment to inflammatory sites (31, 32) and 
implicated in the pathogenesis of CGN (33, 34). Both CTGF and 
FigUre 5 | Treatment with as101 decreases TnFα protein levels and glomerular caspase-3 activity in crescentic glomerulonephritis. Treatment 
protocol was as described in Figure 2. Serum TNFα (a) and glomerular caspase-3 activity (B) were evaluated 2 weeks after αGBM administration (N − 3/group). 
#p < 0.01 increase vs. control; **p < 0.01 decrease vs. αGBM. The one-way ANOVA was used. Immunohistochemistry was performed on kidney sections for 
detection of fibronectin (FN) on week 2 (c). FN expansion was evaluated on weeks 1, 2, 3, and 4 and was scored in 100 glomeruli/sample as follows: grade 0 no 
staining; grade 1 staining occupying up to 25% of glomerular surface area; grade 2 staining occupying 25–50% of glomerular surface area; grade 3 staining 
occupying more than 50% of glomerular surface area (D). Data are presented as mean ± SE of five rats/group for each time point. #p < 0.01 increase vs. control; 
*p < 0.01 decrease vs. αGBM. *p < 0.05 decrease vs. αGBM. The two-way ANOVA was used.
FigUre 6 | Treatment with as101 decreases glomerular macrophage accumulation in crescentic glomerulonephritis. Treatment protocol was as 
described in Figure 2. Immunohistochemistry was performed on kidney sections for detection of glomerular ED-1 positive accumulation on week 2 (a). Glomerular 
macrophages were counted under light microscope. One hundred glomeruli were counted/sample. Treatment starting at day 3 was examined only at week 4 (B). Data 
are presented as mean ± SE of five rats/group for each time point. #p < 0.01 increase vs. control; **p < 0.01 decrease vs. αGBM. The two-way ANOVA was used.
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FigUre 7 | Treatment with as101 decreases glomerular connective tissue growth factor (cTgF) and monocyte chemoattractant protein-1 (McP-1) 
protein expression in crescentic glomerulonephritis and in vitro. Rats were treated as follows: daily i.p. injection with PBS with no αGBM administration 
(control); daily injection with PBS after αGBM injection (αGBM); daily i.p. injection with AS101 (100 μg/rat) starting 6 days after αGBM administration 
(AS101(+6) + αGBM); Glomerular CTGF (a) or MCP-1 (B) protein expression were evaluated on weeks 1, 2, and 3 after αGBM administration. Data are presented 
as mean ± SE of 5 rats/group for each time point. #p < 0.01 increase vs. control; **p < 0.01 decrease vs. αGBM. The two-way ANOVA was used. Glomerular 
mesangial cells were cultured on fibronectin-coated plates with or without various doses of AS101 and 10 μg/ml LPS for 48 h. Supernatants were collected and 
assayed for CTGF (c) and MCP-1 (D) content by ELISA. Results represent mean ± SE of three experiments. *p < 0.05 decrease vs. control; **p < 0.01 decrease 
vs. control. The one-way ANOVA was used.
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MCP-1 were elevated in glomeruli of αGBM-induced rats at all 
time points examined, and both were significantly downregulated 
by AS101 treatment (Figures  7A,B). Expression of CTGF and 
MCP1 in glomeruli and their regulation by AS101 were at least in 
part intrinsic to the glomerular mesangial cells, as AS101 reduced 
production of these factors in mesangial cell cultures in a dose-
dependent fashion (Figures 7C,D).
inactivation of Vla-4 is involved in the 
anti-inflammatory activity of as101 in cgn
Very Late Antigen-4, or α4β1 integrin, is expressed mainly on 
monocytes, lymphocytes, and eosinophils. Blockade of VLA-4 
has been shown to prevent progression of experimental CGN, 
but the mechanisms involved in the beneficial effects of such 
blockade were not elucidated. We recently showed that AS101 
inactivates the VLA-4 integrin by redox modulation of vicinal 
thiols within the exofacial membranal side (12). Recently, another 
integrin, α5β1 (VLA-5), was identified as a cell membrane 
receptor for a parasite-associated protein in human monocytes/
macrophages, leading to activation of caspase-1and IL-1β tran-
scription and indicating that integrin engagement can lead to 
inflammasome activation (35). We therefore hypothesized that 
VLA-4 might have a role in regulating caspase-1 activity and 
that inactivation of VLA-4 might underlie the beneficial activity 
of AS101 in CGN.
To elucidate the role of VLA-4 inactivation by AS101 in GCN 
and to determine whether this activity mediates the anti-inflam-
matory activities of AS101, we first performed in  vitro studies 
involving cultured glomerular macrophages. Figure 8 shows that 
glomerular macrophages secrete substantial amounts of IL-1β in 
response to SAC stimulation and in parallel, their caspase-1 activ-
ity is also elevated (Figures 8A,B). AS101 significantly inhibited 
both these activities in a dose-dependent manner. Glomerular 
macrophage VLA-4 activity was then evaluated by attachment 
to the VLA-4-specific ligand VCAM-1 and to FN while BSA 
served as a global negative control for cell attachment. Treatment 
with AS101 significantly inhibited macrophage attachment to 
both VCAM-1 and FN in a dose-dependent manner, implying 
that AS101 inhibits VLA-4 activity in macrophages (Figure 8C). 
Finally, we examined the role of VLA-4 and VLA-5 on caspase-1 
activation and the effects of AS101 on this process. Figure 8D 
shows that both anti VLA-4- and VLA-5-neutralizing antibodies 
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reduce caspase-1 activity in macrophages, implying the involve-
ment of both integrins in caspase activation. Combined treat-
ment of macrophages with AS101 and anti VLA-4 antibodies 
did not increase the extent of inhibition compared to AS101 and 
anti VLA-4 individually, suggesting that they both may share the 
same target site. In contrast, combined treatment of macrophages 
with anti VLA-5 antibodies and AS101 increased the extent of 
inhibition compared to each one individually, suggesting that 
they use a different binding site. Collectively, these data suggest 
that inhibition of VLA-4 activity by AS101 in macrophages plays 
an important role in caspase-1 inactivation.
attenuation of cgn by as101 is 
associated with inactivation of Vla-4 
in glomerular Macrophages
Experiments designed to measure attachment of macrophages 
isolated from glomeruli of CGN vs. control rats to VCAM-1 or FN 
revealed CGN macrophages attach more strongly to the VLA-4 
ligands than do macrophages from healthy rats, suggesting a very 
high VLA-4 activity (Figure 9A). Treatment of rats with AS101 
starting 3  days after αGBM administration (+3), significantly 
decreased macrophage VLA-4 activity as expressed by a prompt 
decrease in macrophage attachment to VCAM-1 (Figure  9A). 
Furthermore, the decrease in VLA-4 activity in infiltrating mac-
rophages from AS101-treated rats derives from direct inhibition 
of VLA-4 activity and not merely from suppression of VLA-4 
expression (Figure 9B).
These data collectively imply that inactivation of glomerular 
macrophage VLA-4 activity by AS101 and the consequent inac-
tivation of VLA-induced caspase-1 activation could be causally 
connected to attenuation of CGN by the compound.
DiscUssiOn
In this study, we present data showing that administration of the 
non-toxic small molecule tellurium compound, AS101, amelio-
rates crescent formation and preserves renal function in a rat 
model of CGN induced by anti-GBM antibodies. Our data reveal 
that AS101 acts by exerting antiapoptotic and VLA-4-mediated 
FigUre 8 | as101 decreases glomerular caspase-1 activity and glomerular macrophages. IL-1β secretion in vitro. Caspase-1 activity is very late antigen-4 
(VLA-4) dependent. Isolated glomerular macrophages were treated with or without Staphylococcus aureus Cowan I (SAC) (5 μg/ml) and various concentrations of 
AS101 at 106/ml for 24 h. IL-1β (a) and caspase-1 activity (B) were evaluated. #p < 0.01 increase vs. control, *p < 0.01 decrease vs. SAC. The one-way ANOVA 
was used 96-well plates were coated with VCAM-1 or fibronectin (FN) or BSA. Isolated glomerular macrophages were cultured with SAC (5 μg/ml) for 24 h. Cells 
were detached and cultured at 104/well in triplicates in the presence or absence of various AS101 concentrations for 1 h. Non-attached cells were washed out and 
attached cells were quantitated by XTT (c). #p < 0.01 increase vs. BSA; *p < 0.05 decrease vs. AS101 zero (VCAM-1 or FN). The two-way ANOVA was used. 
Isolated glomerular macrophages were cultured as described in (B) in the presence or absence of AS101 (1 μg/ml), αVLA-4 (5 μg/ml), αVLA-5 (5 μg/ml), or their 
combinations, with or without SAC for 24 h. Caspase-1 activity was evaluated (D). #p < 0.01 increase vs. control; **p < 0.01 decrease vs. SAC; *p < 0.05 decrease 
vs. SAC; ##p < 0.05 decrease vs. αVLA-5 without AS101. Data are presented as mean ± SE from four different experiments. The one-way ANOVA was used.
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anti-inflammatory effects both in  vitro and in  vivo through a 
novel mechanism of action.
The rat model of CGN is characterized by clinical deteriora-
tion of kidney function as a result of excessive inflammatory pro-
cesses followed by glomerular crescents formation and eventually 
glomerulosclerosis.
Apart from the role of humoral immunity in CGN, the 
involvement of T  cells and macrophages has been long been 
recognized (33, 36, 37), suggesting an additional contribution 
of cell-mediated immunity in the pathology of the disease. 
Although VLA-4 inactivation by AS101 might also affect adaptive 
immune responses, the study focuses on the role of glomerular 
macrophage VLA-4 deactivation by AS101 in AS101’s beneficial 
effects in this disease. This is in light of numerous reports show-
ing that macrophages are key effectors of disease progression in 
crescentic GN.
Our study establishes that administration of AS101 either 
before or after induction of CGN ameliorates renal function and 
crescent formation. This was associated with profound inhibition 
of inflammatory mediators including active caspase-1, IL-1β, 
IL-18, MCP-1, and CTGF, and with inhibition of FN glomerular 
expansion. These were accompanied by decreased glomerular 
infiltration of macrophages. Monocytes/macrophages play an 
important role in the induction of CGN and glomerular injury 
(5). Their accumulation has been associated with increased 
IL-1β and IL-18 levels in various inflammatory states (30). 
Moreover, IL-18 and IL-1β contribute to crescent formation 
and inflammatory cell recruitment (21, 22). IL-18 is known to 
induce the production of proinflammatory cytokines like TNFα 
and IL-1β (27). Importantly, neutralization of endogenous IL-18 
and TNF-α has been reported to reduce crescent formation, and 
tubulointerstitial scarring, with preservation of renal function, 
in experimental CGN (8, 21). Our study shows positive and 
significant correlations between the decrease of these inflamma-
tory mediators by AS101 and the amelioration increscent forma-
tion, kidney function, and macrophage recruitment. Notably, 
FigUre 9 | Treatment with as101 decreases very late antigen-4 (Vla-4) activity on glomerular macrophages. Rats were treated as follows: daily i.p. 
injection with PBS with no αGBM administration (control); daily injection with PBS of αGBM-induced rats (aGBM); daily i.p. injection with AS101 (100 μg/rat) starting 
3 days after αGBM administration (AS101 (+3) + αGBM); At day 14 after αGBM administration, macrophages were isolated from glomeruli of treated rats and 
cultured on VCAM-1, fibronectin, or BSA-coated microwells at 104/well in triplicates for 1 h. Non-attached cells were washed out and the extent of the remaining 
attached cells was evaluated by XTT (a). Data are presented as mean ± SE from four rats/group. #p < 0.01 increase vs. control; **p < 0.01 decrease vs. αGBM. 
The two-way ANOVA was used (a). Rats were treated with anti-glomerular basement membrane (anti-GBM) and PBS or with anti-GBM and AS101(+3). At 2 weeks 
after anti-GBM administration, macrophages were isolated from glomeruli of rats and evaluated for VLA-4 expression by fluorescence-activated cell sorter analysis. 
(B) Results show one representative experiment of four rats/group analyzed.
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CTGF and MCP-1, which are downregulated in glomeruli of 
AS101-treated rats, were shown to be implicated in monocyte 
recruitment to inflammatory sites (9, 11) and in the pathogenesis 
of CGN (33, 34). The study shows a dramatic increase in FN 
expansion in glomeruli of diseased rats. During inflammation, 
both glomerular accumulation and synthesis of FN has been 
reported (32). Treatment with AS101 significantly inhibited 
this process irrespective of whether AS101 was administered 
starting before or after αGBM administration. There is increasing 
evidence that cytokines such as TNFα, IL-1β, and IL-18 play a 
central role in modulating endothelial function, cellular infil-
tration and proliferation, and extracellular matrix production 
(38). Furthermore, abnormal ECM accumulation plays a role 
in modulating the pattern of synthesis of MCP-1 by glomerular 
mesangial cells (39). Matrix accumulation might also play a role 
in maintaining monocyte infiltration after the development of 
ECM expansion in the subsequent phase of glomerular diseases. 
Expansion of ECM might be involved in the progression of 
glomerular diseases by manipulating the number of infiltrating 
monocytes and stimulation of cytokine gene expression through 
the induction of MCP-1 expression (39). Monocytes are involved 
not only in acute inflammation but also in glomerulosclerosis, 
a feature common to both immune and non-immune forms 
of progressive renal disease (40). Collectively, these data are in 
line with reports showing increased MCP-1 production and FN 
accumulation by CTGF (41, 42).
Previously, VLA-4 has been shown by two studies to prevent 
progression of experimental CGN (43, 44). The mechanisms 
of its beneficial effects were not elucidated. Nevertheless, both 
studies concluded that inhibition of VLA-4 activity does not 
affect leukocytes recruitment to the glomeruli. Our results sug-
gest otherwise. We have recently shown that AS101 inactivates 
the VLA-4 integrin by specific redox modulation (12), driving a 
variety of beneficial biological effects in diverse preclinical and 
clinical studies (14). Our current study demonstrates that AS101 
deactivates macrophage VLA-4 both in  vitro and in  vivo and 
presents evidence that inhibition of caspase-1 activity, associated 
with the anti-inflammatory activity of AS101, is dependent on 
VLA-4 inactivation. We speculate that the apparent discrepancy 
between our data and those of others, who failed to see an effect 
of VLA-4 blockade on macrophage recruitment, results from 
the unique mode of VLA-4 inactivation by AS101 as compared 
to neutralizing VLA-4 antibodies used by others. In fact, the 
possibility remains that similarly to the known phenomenon 
that activation of an integrin by two different ligands may exert 
different outcomes, its inhibition by diverse mechanisms may 
differentially affect cell functions. Although VCAM-1 and FN are 
both ligands for VLA-4, they interact with VLA-4 by a totally dif-
ferent mechanism (45), which might result in distinct functions. 
For example, the interaction between VLA on AML cells and FN 
results in the resistance of leukemic cells to chemotherapy, while 
the interaction of VLA-4 on the same cells with VCAM-1 does 
not (12, 46). Alternatively reduction of infiltrating macrophage 
could not solely depend on blocking the function of VLA-4, 
but may be caused by the overall anti-inflammatory effect of 
AS101, since AS101 can profoundly inhibit several inflamma-
tory cytokines.
Our study is not the first demonstration that an integrin 
can trigger processes leading to production of inflammatory 
mediators. Recently, activation of the α5β1 integrin was shown 
to trigger macrophages to produce an extracellular burst of ATP 
through opening surface pannexin-1 channels that were activated 
by α5β1 integrin signaling in the setting of a pathogen stimulus. 
Subsequently, ATP delivered a critical stimulus to activate the 
NLRP3 inflammasome (35). Furthermore, β1 integrins have 
been reported to function as pathogen recognition receptors on 
intestinal epithelial cells to rapidly induce inflammasome-derived 
IL-18-mediated responses (47). Our results support and expand 
on these studies, and suggest for the first time that caspase-1 activ-
ity is dependent on active VLA-4. Similarly, integrins have been 
previously shown to induce expression of MCP-1 via focal adhe-
sion kinase in mesangial cells (39). Cell adhesion to FN induced 
phosphorylation of FAK and MCP-1 mRNA expression. Our 
in vitro data similarly show MCP-1 and CTGF downregulation 
in mesangial cells cultured on FN-coated plates in the presence 
of AS101. In the aggregate, our data strongly support the inter-
pretation that inactivation of VLA-4 by AS101 leads to decreased 
caspase-1 activity, which brings about a prompt decrease in the 
level of inflammatory cytokines and chemokines produced in the 
glomeruli of diseased rats. This in turn results in decreased ECM 
expansion, reducing macrophage accumulation in the glomeruli 
and ameliorating glomerular cell death and glomerular fibrosis, 
which results in preservation of kidney function.
Besides our prototype tellurium compound AS101, the inves-
tigation of therapeutic activities of other tellurium (IV) com-
pounds is scarce in the literature, although tellurium is the fourth 
most abundant trace element in the human body. Our integrated 
results show that amelioration of the clinical status of rats with 
CGN can be achieved by inhibition of VLA-4 on glomerular 
macrophages leading to decreased caspase-1 activity followed by 
a significant decrease in inflammation. This regulation may be 
achieved using AS101, currently being tested in clinical trials and 
might be beneficial in the treatment of patients with CGN.
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